# Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy

> **NCT01625741** · PHASE2 · TERMINATED · sponsor: **Cliniques universitaires Saint-Luc- Université Catholique de Louvain** · enrollment: 6 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01625741
- **Lead sponsor:** Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Stopped by Principal Investigator decision
- **Last updated:** 2015-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01625741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01625741, "Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01625741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*